Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.
Palvella Therapeutics (NASDAQ:PVLA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Palvella Therapeutics (NASDAQ:PVLA) was given a new $145.00 price target on by analysts at Stifel Nicolaus.
Palvella Therapeutics (NASDAQ:PVLA) was upgraded by analysts at Raymond James Financial, Inc. from an "outperform" rating to a "strong-buy" rating. They now have a $143.00 price target on the stock, up previously from $92.00.